methyl (2S)-2-[[(2R)-3-[4-(aminomethyl)phenyl]-2-(benzylsulfonylamino)propanoyl]amino]-3-(4-aminophenyl)propanoate | 1421446-31-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl (2S)-2-[[(2R)-3-[4-(aminomethyl)phenyl]-2-(benzylsulfonylamino)propanoyl]amino]-3-(4-aminophenyl)propanoate
• CAS: 1421446-31-2
• 化学式: C₂₇H₃₂N₄O₅S
• 分子量: 524.641
• InChiKey: BTZHOXKVRFYOBU-RPBOFIJWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  37
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  162
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  methyl (2S)-2-[[(2R)-3-[4-(aminomethyl)phenyl]-2-(benzylsulfonylamino)propanoyl]amino]-3-(4-aminophenyl)propanoate 在 sodium hydroxide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 0.17h， 生成
  参考文献：
  名称：

  Development of New Cyclic Plasmin Inhibitors with Excellent Potency and Selectivity

  摘要：

  The trypsin-like serine protease plasmin is a target for the development of antifibrinolytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to reduce excessive blood loss. The optimization of our recently described substrate-analogue plasmin inhibitors, which were cyclized between their P3 and P2 side chains, provided a new series with improved efficacy and excellent selectivity. The most potent inhibitor 8 binds to plasmin with an inhibition constant of 0.2 nM, whereas K-i values >1 mu M were determined for nearly all other tested trypsin-like serine proteases, with the exception of trypsin, which is also inhibited in the nanomolar range. Docking studies revealed a potential binding mode in the widely open active site of plasmin that explains the strong potency and selectivity profile of these inhibitors. The dialkylated piperazine-linker segment contributes to an excellent solubility of all analogues. Based on their overall profile the presented inhibitors are well suited for further development as injectable antifibrinolytic drugs.

  DOI：

  10.1021/jm3012917
• 作为产物：
  描述：

  methyl L-4'-aminophenylalanate hydrochloride 在 氢溴酸 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.67h， 生成 methyl (2S)-2-[[(2R)-3-[4-(aminomethyl)phenyl]-2-(benzylsulfonylamino)propanoyl]amino]-3-(4-aminophenyl)propanoate
  参考文献：
  名称：

  Development of New Cyclic Plasmin Inhibitors with Excellent Potency and Selectivity

  摘要：

  The trypsin-like serine protease plasmin is a target for the development of antifibrinolytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to reduce excessive blood loss. The optimization of our recently described substrate-analogue plasmin inhibitors, which were cyclized between their P3 and P2 side chains, provided a new series with improved efficacy and excellent selectivity. The most potent inhibitor 8 binds to plasmin with an inhibition constant of 0.2 nM, whereas K-i values >1 mu M were determined for nearly all other tested trypsin-like serine proteases, with the exception of trypsin, which is also inhibited in the nanomolar range. Docking studies revealed a potential binding mode in the widely open active site of plasmin that explains the strong potency and selectivity profile of these inhibitors. The dialkylated piperazine-linker segment contributes to an excellent solubility of all analogues. Based on their overall profile the presented inhibitors are well suited for further development as injectable antifibrinolytic drugs.

  DOI：

  10.1021/jm3012917

文献信息

• Development of New Cyclic Plasmin Inhibitors with Excellent Potency and Selectivity
  作者：Sebastian M. Saupe、Stephanie Leubner、Michael Betz、Gerhard Klebe、Torsten Steinmetzer

  DOI：10.1021/jm3012917

  日期：2013.2.14

  The trypsin-like serine protease plasmin is a target for the development of antifibrinolytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to reduce excessive blood loss. The optimization of our recently described substrate-analogue plasmin inhibitors, which were cyclized between their P3 and P2 side chains, provided a new series with improved efficacy and excellent selectivity. The most potent inhibitor 8 binds to plasmin with an inhibition constant of 0.2 nM, whereas K-i values >1 mu M were determined for nearly all other tested trypsin-like serine proteases, with the exception of trypsin, which is also inhibited in the nanomolar range. Docking studies revealed a potential binding mode in the widely open active site of plasmin that explains the strong potency and selectivity profile of these inhibitors. The dialkylated piperazine-linker segment contributes to an excellent solubility of all analogues. Based on their overall profile the presented inhibitors are well suited for further development as injectable antifibrinolytic drugs.